Eli Lilly halves €2.3B Germany investment plan amid strategic pullback

Eli Lilly will halve its planned €2.3 billion investment in Germany, the company said June 3, scaling back what was one of the largest pharmaceutical manufacturing commitments in Europe.

The original plan, announced in 2024, called for a €2.3 billion expansion of Lilly's site in Alzey, Germany, to boost production of injectable medicines and diabetes drugs. The company now expects to invest roughly half that amount, according to a person familiar with the matter.

"After a thorough review of our global manufacturing footprint and capital allocation priorities, we have adjusted the scope of the Alzey project," a Lilly spokesperson said. "Germany remains an important market for Lilly, but we must deploy capital where it generates the strongest returns."

The decision comes as Lilly has been on an acquisition spree, with its top dealmaker recently signaling more M&A that could push the company into new therapeutic areas. The company has struck multiple deals this year, including agreements disclosed in recent weeks, as it deploys cash from its blockbuster obesity and diabetes franchise into pipeline expansion.

The pullback in Germany raises questions about the country's competitiveness as a pharmaceutical investment destination. Europe has been grappling with higher energy costs, regulatory complexity, and slower drug pricing negotiations compared with the US. The cut also contrasts with Lilly's aggressive expansion in other regions, including a $4.5 billion manufacturing campus in Indiana announced last year.

Shares of Lilly traded lower on the news, extending a recent pullback. The stock has gained roughly 30% over the past 12 months, driven by sales of its GLP-1 drugs Mounjaro and Zepbound, but has faced pressure from investor concerns about pricing and competition.

For holders, the investment cut signals a more cautious approach to European capital deployment as Lilly prioritizes higher-return projects. Investors will watch for further details on the company's capital allocation strategy at its next earnings call, expected in July.

This article is for informational purposes only and does not constitute investment advice.